Pay in 4 interest-free payments of $5.58 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Utilizing its proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies as well as Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has developed multiple drug candidates in-house, including both small molecules and peptides, such as its lead program, ASC30, a small molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management
Consistent with this hypothesis, recent work from the Zhao and Drlica labs has indicated that antibiotic-induced cell death occurs after plating on drug-free agar due, in part, to the post-stress accumulation of reactive oxygen species (ROS) 11 , so that cell death may occur significantly after plating
Xue B et al
Each component of our stacks is individually verified by two independent analyses before co-formulation: HPLC chromatography (purity 98%) and LC-MS mass spectrometry (confirmation of molecular mass)
US$ 29.51
US$ 26.05
US$ 28.66
